Literature DB >> 27172639

Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.

Gary Levy, John Elkas, Alicia Y Armstrong, Lynnette K Nieman.   

Abstract

BACKGROUND: Prolonged exposure to a selective progesterone receptor modulator (ulipristal acetate) in a patient with benign metastasizing leiomyoma did not result in endometrial hyperplasia or neoplasia. CASE: A woman with history of benign metastasizing leiomyoma underwent medical treatment for 5 years with ulipristal acetate. Endometrial biopsies were performed at established intervals to monitor for intraepithelial neoplasia or progesterone receptor modulator-associated endometrial changes (PAECs). The patient tolerated UPA therapy well; there was no evidence of hyperplasia or proliferative changes associated with progesterone-associated endometrial changes.
CONCLUSION: In this case prolonged exposure to ulipristal acetate did not result in premalignant or malignant endometrial pathology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27172639      PMCID: PMC9552277     

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.218


  23 in total

1.  The spectrum of endometrial pathology induced by progesterone receptor modulators.

Authors:  George L Mutter; Christine Bergeron; Liane Deligdisch; Alex Ferenczy; Mick Glant; Maria Merino; Alistair R W Williams; Diana L Blithe
Journal:  Mod Pathol       Date:  2008-02-08       Impact factor: 7.842

2.  Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas.

Authors:  Steven H Eisinger; Thomas Bonfiglio; Kevin Fiscella; Sean Meldrum; David S Guzick
Journal:  J Minim Invasive Gynecol       Date:  2005 May-Jun       Impact factor: 4.137

3.  Ulipristal acetate versus placebo for fibroid treatment before surgery.

Authors:  Jacques Donnez; Tetyana F Tatarchuk; Philippe Bouchard; Lucian Puscasiu; Nataliya F Zakharenko; Tatiana Ivanova; Gyula Ugocsai; Michal Mara; Manju P Jilla; Elke Bestel; Paul Terrill; Ian Osterloh; Ernest Loumaye
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

4.  Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.

Authors:  Alistair R W Williams; Christine Bergeron; David H Barlow; Alex Ferenczy
Journal:  Int J Gynecol Pathol       Date:  2012-11       Impact factor: 2.762

5.  Management of patients receiving long-term treatment with mifepristone.

Authors:  Irving M Spitz; Steven M Grunberg; Nathalie Chabbert-Buffet; Tzina Lindenberg; Hadassa Gelber; Regine Sitruk-Ware
Journal:  Fertil Steril       Date:  2005-12       Impact factor: 7.329

6.  A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.

Authors:  Kristof Chwalisz; Lois Larsen; Cynthia Mattia-Goldberg; Anthony Edmonds; Walter Elger; Craig A Winkel
Journal:  Fertil Steril       Date:  2007-02-20       Impact factor: 7.329

7.  Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial.

Authors:  Kevin Fiscella; Steven H Eisinger; Sean Meldrum; Changyong Feng; Susan G Fisher; David S Guzick
Journal:  Obstet Gynecol       Date:  2006-12       Impact factor: 7.661

8.  Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial.

Authors:  M Engman; S Granberg; A R W Williams; C X Meng; P G L Lalitkumar; K Gemzell-Danielsson
Journal:  Hum Reprod       Date:  2009-04-23       Impact factor: 6.918

9.  Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study.

Authors:  Oskari Heikinheimo; Susheel Vani; Olli Carpén; Annamaija Tapper; Päivi Härkki; Eeva-Marja Rutanen; Hilary Critchley
Journal:  Hum Reprod       Date:  2007-07-17       Impact factor: 6.918

10.  Ulipristal acetate, a progesterone receptor modulator for emergency contraception.

Authors:  Shilpa P Jadav; Dinesh M Parmar
Journal:  J Pharmacol Pharmacother       Date:  2012-04
View more
  4 in total

Review 1.  Update on medical treatment for Cushing's disease.

Authors:  Daniel Cuevas-Ramos; Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Clin Diabetes Endocrinol       Date:  2016-09-13

2.  Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma.

Authors:  Ana Amélia de Souza; Albina Altemani; Ney Soares de Araujo; Lucas Novaes Texeira; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Clin Pathol       Date:  2019-09-26

3.  Treatment of endometriosis-related chronic pelvic pain with Ulipristal Acetate and associated endometrial changes.

Authors:  Leah Hawkins Bressler; Lia A Bernardi; Mallory A Snyder; Jian-Jun Wei; Serdar Bulun
Journal:  HSOA J Reprod Med Gynaecol Obstet       Date:  2017-12-30

Review 4.  Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.

Authors:  Mohamed Ali; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2017-09-01       Impact factor: 4.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.